share_log

Goldman Sachs Maintains Neutral on Alterity Therapeutics, Lowers Price Target to $3

Benzinga Real-time News ·  Jun 23, 2022 07:18

Goldman Sachs maintains Alterity Therapeutics (NASDAQ:ATHE) with a Neutral and lowers the price target from $11 to $3.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment